A new cancer immunotherapy suffers a setback – Science Magazine
Science Magazine |
A new cancer immunotherapy suffers a setback
Science Magazine The surprising failure last month of a large clinical trial of a promising cancer immunotherapy drug from the biotech company Incyte has quickly reverberated across the pharmaceutical industry. Three companies have canceled, suspended, or downsized 12 … |
